Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

Ecotrade Group Highlights Its Digital Catalytic Converter Pric...

BANGKOK, July 7, 2020 /PRNewswire-AsiaNet/-- Ecotrade Group[https://www.catalyticconverterrecycling.com/] recently acknowledged the growing popularity of its free pricebook app. Compatible w...

Hong Kong Convention Ambassadors of 12 Sectors Celebrate Achievements of Securing 70 Conventions in Appreciation Night

HONG KONG SAR - Media OutReach Newswire - 22 May 2024 - The Hong Kong Tourism Board (HKTB) hosted the Hong Kong Convention Ambassador (HKCA) Appreciation Night on 20 May (Monday) at Rosewoo...

AsianPLAS 2026 Connects Global Buyers with Plastics Rubber Suppliers Through an Extended Online Exhibition

TAIPEI, TAIWAN - Media OutReach Newswire – 19 August 2026 - Asian Plastics & Rubber Industry Online Exhibition 2026 (AsianPLAS 2026) officially opens on August 19, launching an ex...

Renault-Nissan-Mitsubishi Achieves Record First-Half Sales Of ...

PARIS, TOKYO and YOKOHAMA, Japan, July 27, 2018 /PRNewswire/ -- Sales Rise 5.1 Percent Amid Solid Demand For Models Sold By Alliance Member Companies Renault-Nissan-Mitsubishi, the world's l...

AGNEZ MO Reunites with Wax Figure and Fans at Madame Tussauds Singapore’s Exclusive Fan Meet

SINGAPORE - Media OutReach Newswire - 19 January 2026 - Madame Tussauds Singapore hosted an exclusive fan meet event on 16 January 2026, featuring international music and entertainment...

Argus Collaborates with Microsoft to Bring End-to-End Automoti...

TEL AVIV, Israel, March 30, 2021 /PRNewswire-AsiaNet/-- Argus Cyber Security Suite of Solutions integrated with Microsoft's Azure IoT platform to provide in-vehicle and off-board monitoring...

Plug in and you’re ready to stream: Sennheiser Profile USB microphone provides ease of use and best-in-class audio

WEDEMARK, GERMANY - Media OutReach - 15 March 2023 - Today, Sennheiser is launching the Profile USB microphone, a cardioid condenser microphone that presents an easy and stylish solution ...

FII Institute Partners with Global Leaders at Visionary Riyadh...

RIYADH, Oct. 20, 2022 /PRNewswire-AsiaNet/-- The Future Investment Initiative (FII) Institute today announced key strategic partnerships with some of the world's best-known organizations and...

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

HONG KONG, May 26, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug (generic name: Penpulimab; R&D code: AK105) jointly developed and commercialized with Akeso, Inc. (HKEX: 9926), a biopharmaceutical company committed to R&D, production and commercialization of affordable innovative antibody drugs for patients worldwide, has been accepted by the National Medical Products Administration of the PRC, for the treatment of patients with relapsed or refractory Classical Hodgkin's Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age . cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%. Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment .

Professor Zhu Jun, Co-principal investigator of the lead unit Beijing Cancer Hospital is full of expectations for such a differentiated anti PD-1 monoclonal product and said, through bioengineering technology, Penpulimab completely eliminate the binding activity of Fc receptors and avoid the antibody-dependent cell-mediated cytotoxicity (ADCC) effect. At the same time, compared with other drugs available in the market working on the same target, it has a slower rate of antigen binding and dissociation, which makes the biological effect stronger and improves its anti-tumor activity.

Co-lead researcher Professor Song Yuqin, Director of Lymphoma Department at Peking University Cancer Hospital said, in clinical trial, Penpulimab was observed with gratifying therapeutic data and good safety. As a clinician, Professor Song hoped that Penpulimab can be launched to the market soon, which will benefit more patients and their families.

About Sino Biopharmaceutical Limited (HKEX: 1177)Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng Index - Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index - Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018. http://www.sinobiopharm.com/.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastCrackStreamscialis 20 mg fiyathttps://elektroniksigarakeyfi.net/marka/voopoo/taraftarium24taraftarium24extrabet